NEFL and myeloid sarcoma: Integrating these biomarkers with established tools such as NfL and GFAP could provide a more holistic approach to MS diagnosis, prognosis, and treatment monitoring—particularly in early disease stages, neurocognitive relapses, and tracking disease progression.